Meanwhile, low doses of doxorubicin reduced Akt‐activated β‐catenin levels, thus downregulating diverse immune checkpoints in leukemia stem cells, such as PD‐L1, TIM3, and CD24.40 This evidence concerns the gene CD274 and leukemia.